26 research outputs found
Fetal abdominal cysts: Predicting adverse outcomes
Abdominal; Cyst; PerinatalAbdominal; Quist; PerinatalAbdominal; Quiste; PerinatalIntroduction
The primary aim of the study was to identify risk factors associated with fetal or neonatal loss, neonatal morbidity, and the need for surgery in fetuses diagnosed with an abdominal cyst. The secondary aim was to compare the characteristics of the cyst according to trimester at diagnosis.
Material and methods
This was an observational retrospective study performed at Vall d'Hebron University Hospital. The study included pregnant women aged 18âyears or older with diagnosis of a fetal abdominal cyst from 2008 to 2021.
Results
A total of 82 women with a median gestational age of 31+1 weeks (12+0â39+4) were included in the analysis. Seven (8.5%) cases were diagnosed in the first trimester, 28 (34.1%) in the second trimester, and 47 (57.3%) in the third trimester. Fetal or neonatal loss occurred in 10 (12.2%) cases; significant predictors were diagnosis in the first trimester (OR 36.67, 95% CI: 4.89â274.79), male gender (OR 4.75, 95% CI: 1.13â19.9), and associated abnormalities (OR 15.2, 95% CI: 2.92â79.19). A total of 10 of 75 (13.3%) neonates showed at least one neonatal complication, and the only predictor was occurrence of associated abnormalities (OR 7.36, 95% CI: 1.78â30.51). A total of 16 of 75 (21.3%) neonates required postnatal surgery, and the predictors were second-trimester diagnosis (OR 3.92, 95% CI: 1.23â12.51), associated abnormalities (OR 3.81, 95% CI: 1.15â12.64), and bowel location (OR 10.0, 95% CI: 1.48â67.55).
Conclusions
Factors associated with adverse outcomes in fetuses diagnosed with abdominal cysts are first-trimester diagnosis and associated abnormalities. Cysts detected in the second trimester and those of intestinal origin are more likely to require surgery
Releases of PCDD/Fs, PCBs, PAHs and HCB Through Bottom Ashes from Brick Kilns Operating with Different Kind of Fuels - Results from a Pilot Study in Mexico - A Contribution to the Update and Review of the Standardized Toolkit for Identification and Quantification of Dioxin and Furan Releases
The Standardized Toolkit for Identification and Quantification of Dioxin and Furan Releases is aimed at supporting the parties to the Stockholm Convention (SC) on Persistent Organic Pollutants (POPs) in setting up their national implementation plan, which includes the characterization of unintentional releases of POPs (in this case PCDD/Fs, PCBs and HCB) from all relevant sectors. To this end the toolkit combines sector specific activity data with related emission factors for releases to air, land, water, residues and products.
In 2007 the Expert Group for updating and improving the Toolkit, chaired by the Secretariat of the SC (SSC) and UNEP, identified priority areas of reasearch. The group highlighted the need for screening POPs sources that so far are poorly characterized in the Toolkit. Among these, brick kilns in developing countries were given highest priority since so far, no data were available.
The Expert Group recommended as a first step to measure soil or vegetation samples close to (small) brick kilns in developing countries to obtain preliminary orientation as to the impact from this source.
In the fore field of the experimental planning the question in how far different kinds of fuels, in particular waste derived fuels, may impact the formation of POPs was approached through the analyses of bottom ashes from kilns co-incinerating waste in comparison with brick kilns operated with virgin wood.
The results from bottom ash reveal a distinct impact on the presence of POPs in the brick making process when waste is co-incinerated, thus suggesting to include the brick kilns operated with waste fuels as a different category into the toolkit and to include the issue of co-incineration of waste into the experimental set up.
The emission factors via the bottom ashes itself rangeJRC.H.5-Rural, water and ecosystem resource
Fetal Transient Skin Edema in Two Pregnant Women With Coronavirus Disease 2019 (COVID-19)
Altres ajuts: Funding was provided for the Gesta-COVID19 Study by Instituto de Salud Carlos III (ISCIII) (PR(AMI)181/2020) (ISCIII's reference: COV20/00188).Fetal skin edema in the second trimester might be associated with maternal coronavirus disease 2019 (COVID-19). The risk of vertical transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains unknown. Positive reverse-transcription polymerase chain reaction (RT-PCR) test results for SARS-CoV-2 infection in neonates and placental tissue have been reported, and immunoglobulin M antibodies have been detected in neonates born to mothers with infection. The first case is a woman at 22 3/7 weeks of gestation with coronavirus disease 2019 (COVID-19) who was admitted to the intensive care unit. In the second case, the patient remained at home with mild symptoms, starting at 20 weeks of gestation. In both cases, fetal skin edema was observed on ultrasound examination while maternal SARS-COV-2 RT-PCR test results were positive and resolved when maternal SARS-COV-2 RT-PCR test results became negative. The RT-PCR test result for SARS-CoV-2 in amniotic fluid was negative in both cases. The two pregnancies are ongoing and uneventful. Transient fetal skin edema noted in these two patients with COVID-19 in the second trimester may represent results of fetal infection or altered fetal physiology due to maternal disease or may be unrelated to the maternal illness
PCDD/PCDF, PCB, and Hexachlorobenzene in soil, bottom ash and products from brickmaking sites in developing countries - Results from surveys in Kenya, Mexico, and South Africa. A contribution to the Standardized Toolkit for Identification and Quantification of Dioxin and Furan Releases in support to the Stockholm Convention on Persistent Organic Pollutants
The report combines the results from soil sampling campaigns executed in Mexico, South Africa and Kenya in order to assess the impact of artisanal brick making on local environments. Moreover the study serves indirectly (through the comparison of the impact on soils), whether the emission factors for brick kilns obtained in in a separate study in Mexico can be applied to other developing countries. These emission factors will be introduced into the calculation scheme for the National Emission Inventories of unintentional POP's releases ("dioxin toolkit) which is the reporting tool under the reporting obligations laid down in the Stockholm Convention of POPs.
Results revealed, that the soils in Mexico are higher contaminated then in South Africa and Kenya, most probably due to the practice of co-incineration of waste (oils), whereas in Africa coal or virgin biomass are used as fuels.
In so far the emission factors obtained in Mexico apparently represent the upper range of emission factors for brick making.JRC.D.2-Water and Marine Resource
Gestational age-based reference ranges for cervical length and preterm birth prediction in triplet pregnancies: an observational retrospective study
Cervical length; Preterm delivery; Triplet pregnancyLongitud cervical; Parto prematuro; Embarazo de trillizosLongitud cervical; Part prematur; EmbarĂ s de trillissosObjectives
To develop gestational age-based reference ranges for cervical length in triplet pregnancies. The secondary objective was to assess the performance of cervical length measured between 18 and 20â+â6 days for the prediction of preterm delivery before 28 and 32 weeks, respectively.
Methods
Observational retrospective study of triplet pregnancies in three Spanish tertiary-care hospitals between 2001 and 2019. Cervical length measurements were consecutively obtained between 15 and 34 weeks of gestation. Pregnancies undergoing multifetal reduction or fetal surgery were excluded.
Results
Two hundred and six triplet pregnancies were included in the final analysis. There was a quadratic decrease in cervical length with gestational age. The median and fifth centiles for cervical length at 20 weeks were 35 and 13 mm. In the prediction of preterm birthâ<â28 weeks, for a false positive rate of 5%, and 10%, the detection rates were 40.9%, and 40.9%, respectively, and the prediction of preterm birthâ<â32 weeks, 22.0% and 26.0%, respectively.
Conclusions
In triplet pregnancies, cervical length decreases with gestational age. The performance of cervical length at 18â20â+â6 in screening for preterm birth before 28 and 32 weeks is poor
The Tarantula Massive Binary Monitoring VI: Characterisation of hidden companions in 51 single-lined O-type binaries, a flat mass-ratio distribution, and black-hole binary candidates
We aim to hunt for massive binaries hosting a black hole companion (OB+BH)
and establish the natal mass-ratio distribution of massive stars at the
subsolar metallicity environment of the Large Magellanic Cloud (LMC). To this
end, we use the shift-and-add grid disentangling technique to characterize the
hidden companions in 51 SB1 O-type and evolved B-type binaries in the LMC
monitored in the framework of the Tarantula Massive Binary Monitoring (TMBM).
We find that, out of the 51 SB1 systems, 43 (84%) are found to have
non-degenerate stellar companions, of which 28 are confident detections, and 15
are less certain (SB1: or SB2:). Of these 43 targets, one is found to be a
triple (VFTS 64), and two are found to be quadruples (VFTS 120, 702). The
remaining eight targets (16%) retain an SB1 classification. Aside from the
unambiguous case of VFTS 243, analysed in detailed in a separate paper, we
identify two additional OB+BH candidates: VFTS 514 and VFTS 779. Additional
black holes may be present in the sample but at a lower probability. Our study
firmly establishes a virtually flat natal mass-ratio distribution for O-type
stars at LMC metallicity, covering the entire mass-ratio range (0.05 < q < 1)
and periods in the range 0 < log P < 3 [d]. The nature of the OB+BH candidates
should be verified through future monitoring, but the frequency of OB+BH
candidates is generally in line with recent predictions at LMC metallicity.Comment: 41 pages (14 main article + 27 appendix), recommended for acceptance
in A&A pending minor revisions, comments welcom
Gestation and COVID-19 : clinical and microbiological observational study (Gesta-COVID19)
The Coronavirus Disease 2019 (COVID-19) is a novel disease which has been having a worldwide affect since December 2019. Evidence regarding the effects of SARS-CoV-2 during pregnancy is conflicting. The presence of SARS-CoV-2 has been demonstrated in biological samples during pregnancy (placenta, umbilical cord or amniotic fluid); however, maternal and fetal effects of the virus are not well known. Descriptive, multicentre, longitudinal, observational study in eight tertiary care hospitals throughout Spain, that are referral centres for pregnant women with COVID-19. All pregnant women with positive SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction during their pregnancy or 14 days preconception and newborns born to mothers infected with SARS-CoV-2 will be included. They will continue to be followed up until 4 weeks after delivery. The aim of the study is to investigate both the effect of COVID-19 on the pregnancy, and the effect of the pregnancy status with the evolution of the SARS-CoV-2 disease. Other samples (faeces, urine, serum, amniotic fluid, cord and peripheral blood, placenta and breastmilk) will be collected in order to analyse whether or not there is a risk of vertical transmission and to describe the behaviour of the virus in other fluids. Neonates will be followed until 6 months after delivery to establish the rate of neonatal transmission. We aim to include 150 pregnant women and their babies. Ethics approval will be obtained from all the participating centres. There is little information known about COVID-19 and its unknown effects on pregnancy. This study will collect a large number of samples in pregnant women which will allow us to demonstrate the behaviour of the virus in pregnancy and postpartum in a representative cohort of the Spanish population
Confirmation of preeclampsia-like syndrome induced by severe COVID-19 : An Observational Study
Since the outbreak of the COVID-19 pandemic, some studies have reported an increased preeclampsia (PE) incidence in pregnant women with SARS-CoV-2 infection. Several explanations for this association have been proposed, including a preeclampsia-like syndrome induced by severe COVID-19. This syndrome was described in a small case series and has not been confirmed in larger studies and its impact in perinatal outcomes has not been studied. The aim of this study was to confirm the preeclampsia-like syndrome due to COVID-19 and to investigate its implications in pregnancy outcomes and prognosis. This was a prospective, observational study conducted in a tertiary referral hospital. Inclusion criteria were pregnant women admitted to the Intensive Care Unit for severe pneumonia due to COVID-19. They were classified in three groups based on clinical and laboratory findings: PE, PE-like syndrome, and women without PE features. The three cohorts were analyzed and compared at three different times: before, during and after severe pneumonia. The main outcomes were incidence of adverse perinatal outcomes and signs and symptoms of PE, such as hypertension, proteinuria, thrombocytopenia, elevated liver enzymes and increased angiogenic factors (soluble fms-like tyrosine kinase-1 to placental growth factor ratio [sFlt-1/PlGF]). A total of 106 women were admitted to Intensive Care Unit due to severe pneumonia and 68 were included in the study. Of those, 53 (50.0%) did not meet the diagnostic criteria for PE and remained pregnant after pneumonia (non-PE), seven (6.6%) met the diagnostic criteria for PE, had abnormal (>38) sFlt-1/PlGF (PE) and delivered during severe pneumonia, and eight (7.5%) met the diagnostic criteria for PE, had normal (â€38) sFlt-1/PlGF (PE-like) and did not deliver during pneumonia. Despite not having delivered, most PE-related features improved after severe pneumonia in women with PE-like syndrome. Women with PE had significantly poorer outcomes than women with PE-like syndrome or without PE. More than 50% of women with severe COVID-19 and diagnostic criteria for PE may not be PE but a PE-like syndrome, which may affect up to 7.5% of women with severe COVID-19. PE-like syndrome might have similar perinatal outcomes to those of normotensive women with severe pneumonia due to COVID-19. For these reasons, PE-like syndrome should be excluded by using sFlt-1/PlGF in future research and before making clinical decisions
Confirmation of preeclampsia-like syndrome induced by severe COVID-19: an observational study
COVID-19; Preeclampsia; PregnancyCOVID-19; Preeclampsia; EmbarazoCOVID-19; Preeclampsia; EmbarĂ sBACKGROUND
Since the outbreak of the COVID-19 pandemic, some studies have reported an increased preeclampsia incidence in pregnant women with SARS-CoV-2 infection. Several explanations for this association have been proposed, including a preeclampsia-like syndrome induced by severe COVID-19. This syndrome was described in a small case series and has not been confirmed in larger studies, and its effect on perinatal outcomes has not been studied.
OBJECTIVE
This study aimed to confirm the preeclampsia-like syndrome because of COVID-19 and to investigate its implications on pregnancy outcomes and prognosis.
STUDY DESIGN
This was a prospective, observational study conducted in a tertiary referral hospital. The inclusion criteria were pregnant women admitted to the intensive care unit for severe pneumonia because of COVID-19. They were classified into 3 groups based on clinical and laboratory findings: preeclampsia, preeclampsia-like syndrome, and women without preeclampsia features. The 3 cohorts were analyzed and compared at 3 different times: before, during, and after severe pneumonia. The main outcomes were incidence of adverse perinatal outcomes and signs and symptoms of PE, such as hypertension, proteinuria, thrombocytopenia, elevated liver enzymes, and increased angiogenic factors (soluble fms-like tyrosine kinase 1âtoâplacental growth factor ratio).
RESULTS
A total of 106 women were admitted to the intensive care unit because of severe pneumonia, and 68 women were included in the study. Of those, 53 (50.0%) did not meet the diagnostic criteria for preeclampsia and remained pregnant after pneumonia (non-preeclampsia); 7 (6.6%) met the diagnostic criteria for preeclampsia, had abnormal (>38) soluble fms-like tyrosine kinase 1âtoâplacental growth factor ratio (preeclampsia), and delivered during severe pneumonia, and 8 (7.5%) met the diagnostic criteria for preeclampsia, had normal (â€38) soluble fms-like tyrosine kinase 1âtoâplacental growth factor ratio (preeclampsia like), and did not deliver during pneumonia. Despite not having delivered, most preeclampsia-related features improved after severe pneumonia in women with preeclampsia-like syndrome. Women with preeclampsia had significantly poorer outcomes than women with preeclampsia-like syndrome or without preeclampsia.
CONCLUSION
More than 50% of women with severe COVID-19 and diagnostic criteria for preeclampsia may not be preeclampsia but a preeclampsia-like syndrome, which may affect up to 7.5% of women with severe COVID-19. Preeclampsia-like syndrome might have similar perinatal outcomes to those of normotensive women with severe pneumonia because of COVID-19. For these reasons, preeclampsia-like syndrome should be excluded by using soluble fms-like tyrosine kinase 1âtoâplacental growth factor ratio in future research and before making clinical decisions
Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune Mediated Inflammatory Diseases. A Multicenter Study
We aimed to assess the e cacy of biologic therapy in refractory non-Multiple Sclerosis
(MS) Optic Neuritis (ON), a condition more infrequent, chronic and severe than MS ON. This was
an open-label multicenter study of patients with non-MS ON refractory to systemic corticosteroids
and at least one conventional immunosuppressive drug. The main outcomes were Best Corrected
Visual Acuity (BCVA) and both Macular Thickness (MT) and Retinal Nerve Fiber Layer (RNFL) using
Optical Coherence Tomography (OCT). These outcome variables were assessed at baseline, 1 week,
and 1, 3, 6 and 12 months after biologic therapy initiation. Remission was defined as the absence of ON symptoms and signs that lasted longer than 24 h, with or without an associated new lesion
on magnetic resonance imaging with gadolinium contrast agents for at least 3 months. We studied
19 patients (11 women/8 men; mean age, 34.8 13.9 years). The underlying diseases were Bechet?s
disease (n = 5), neuromyelitis optica (n = 3), systemic lupus erythematosus (n = 2), sarcoidosis (n = 1),
relapsing polychondritis (n = 1) and anti-neutrophil cytoplasmic antibody -associated vasculitis (n = 1).
It was idiopathic in 6 patients. The first biologic agent used in each patient was: adalimumab (n = 6),
rituximab (n = 6), infliximab (n = 5) and tocilizumab (n = 2). A second immunosuppressive drug was
simultaneously used in 11 patients: methotrexate (n = 11), azathioprine (n = 2), mycophenolate mofetil
(n = 1) and hydroxychloroquine (n = 1). Improvement of the main outcomes was observed after 1 year
of therapy when compared with baseline data: mean SD BCVA (0.8 0.3 LogMAR vs. 0.6 0.3
LogMAR; p = 0.03), mean SD RNFL (190.5 175.4 m vs. 183.4 139.5 m; p = 0.02), mean SD
MT (270.7 23.2 m vs. 369.6 137.4 m; p = 0.03). Besides, the median (IQR) prednisone-dose was
also reduced from 40 (10?61.5) mg/day at baseline to. 2.5 (0?5) mg/day after one year of follow-up;
p = 0.001. After a mean SD follow-up of 35 months, 15 patients (78.9%) achieved ocular remission,
and 2 (10.5%) experienced severe adverse events. Biologic therapy is e ective in patients with
refractory non-MS ON